CMP Pharma

Executive Summary

CMP Pharma is a private pharmaceutical company based in Farmville, USA, that developed and markets the first FDA-approved oral solution of amlodipine, a calcium channel blocker used to treat hypertension and coronary artery disease. The product is approved for adults and children aged 6 and older, offering a unique liquid formulation that addresses an unmet need for patients who have difficulty swallowing tablets or require flexible dosing. Since its founding in 1975, the company has focused on this single approved product, positioning itself as a niche player in the cardiovascular space. With no disclosed pipeline, CMP Pharma's current value is tied to the commercial performance of this oral solution. As an approved product, CMP Pharma's near-term outlook depends on market adoption, payer coverage, and potential label expansions. While the company benefits from being the first-to-market in this formulation, it faces competition from generic amlodipine tablets and other antihypertensives. Key growth drivers include expanding pediatric use, securing formulary access, and leveraging partnerships for broader distribution. Given the company's mature stage and lack of disclosed pipeline, conviction is moderate, as revenue growth is likely incremental rather than transformative.

Upcoming Catalysts (preview)

• TBDLabel expansion to include children under 630% success
• TBDStrategic partnership or licensing deal for commercialization50% success
• TBDPositive clinical data for new indication (e.g., pediatric hypertension)20% success